[go: up one dir, main page]

TR199901133T2 - Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide. - Google Patents

Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.

Info

Publication number
TR199901133T2
TR199901133T2 TR1999/01133T TR9901133T TR199901133T2 TR 199901133 T2 TR199901133 T2 TR 199901133T2 TR 1999/01133 T TR1999/01133 T TR 1999/01133T TR 9901133 T TR9901133 T TR 9901133T TR 199901133 T2 TR199901133 T2 TR 199901133T2
Authority
TR
Turkey
Prior art keywords
inhibit
synthesis
compounds
release
methods
Prior art date
Application number
TR1999/01133T
Other languages
Turkish (tr)
Inventor
E. Audia James
C. Britton Thomas
J. Droste James
K. Folmer Beverly
W. Huffman George
John Verghese
H. Latimer Lee
E. Mabry Thomas
S. Nissen Jeffrey
J. Porter Warren
K. Reel Jon
D. Thorsett Eugene
S. Tung Jay
Wu Jing
Norman Eid Clark
Leonard Scott William
Original Assignee
Elan Pharmaceuticals, Inc.
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals, Inc., Eli Lilly And Company filed Critical Elan Pharmaceuticals, Inc.
Publication of TR199901133T2 publication Critical patent/TR199901133T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

-Amiloid peptidinin salinmasini ve/veya sentezini inhibe eden ve dolayisiyla Alzheimer hastaliginin tedavisinde kullanilabilen bilesikler açiklanmaktadir.Ayrica -Amiloid peptidinin salinmasini ve/veya sentezini inhibe eden bir bilesik içeren farmasötik bilesimler ve Alzheimer hastaliginin böyle bilesimlerle profilaktik ve terapötik tedavisi için yöntemler açiklanmaktadir. - Compounds that inhibit the release and / or synthesis of the amyloid peptide and therefore can be used in the treatment of Alzheimer's disease are described.

TR1999/01133T 1996-11-22 1997-11-21 Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide. TR199901133T2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75544296A 1996-11-22 1996-11-22
US80752897A 1997-02-28 1997-02-28
US80852897A 1997-02-28 1997-02-28
US80742797A 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
TR199901133T2 true TR199901133T2 (en) 1999-07-21

Family

ID=27505670

Family Applications (3)

Application Number Title Priority Date Filing Date
TR1999/01133T TR199901133T2 (en) 1996-11-22 1997-11-21 Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.
TR1999/02937T TR199902937T2 (en) 1996-11-22 1997-11-21 Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.
TR1999/02938T TR199902938T2 (en) 1996-11-22 1997-11-21 Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.

Family Applications After (2)

Application Number Title Priority Date Filing Date
TR1999/02937T TR199902937T2 (en) 1996-11-22 1997-11-21 Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.
TR1999/02938T TR199902938T2 (en) 1996-11-22 1997-11-21 Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.

Country Status (21)

Country Link
EP (1) EP0942924A2 (en)
JP (1) JP2001503782A (en)
KR (1) KR20000069064A (en)
CN (1) CN1238779A (en)
AR (1) AR016751A1 (en)
AU (1) AU5356198A (en)
BR (1) BR9713400A (en)
CA (1) CA2267634A1 (en)
CO (1) CO4910156A1 (en)
CZ (1) CZ122899A3 (en)
EA (1) EA199900490A1 (en)
HR (1) HRP970627A2 (en)
HU (1) HUP0100270A3 (en)
ID (1) ID22044A (en)
IL (1) IL129083A0 (en)
NO (1) NO992368L (en)
NZ (1) NZ334690A (en)
PE (1) PE16999A1 (en)
TR (3) TR199901133T2 (en)
WO (1) WO1998022494A2 (en)
YU (1) YU46097A (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
JP2002518451A (en) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド Cyclic amino acid compound and pharmaceutical composition thereof, and method of inhibiting release of β-amyloid peptide and / or synthesis thereof using the compound
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
JP2002518483A (en) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド Compounds for inhibiting β-amyloid peptide release and / or their synthesis
DE19828113A1 (en) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
EP1131634A2 (en) 1998-09-30 2001-09-12 Elan Pharmaceuticals, Inc. Determining the mechanism of beta-amyloid peptide generation
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
JP2002531576A (en) 1998-12-10 2002-09-24 エフ．ホフマン−ラ ロシュ アーゲー Procollagen C-proteinase inhibitor
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
IL146312A0 (en) * 1999-05-07 2002-07-25 Texas Biotechnology Corp Propanoic acid derivatives that inhibit the binding of integrins to their receptors
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
EP1235789A2 (en) * 1999-11-09 2002-09-04 Eli Lilly And Company $g(b)-AMINOACID COMPOUNDS USEFUL FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
IL151368A0 (en) 2000-03-31 2003-04-10 Probiodrug Ag Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
WO2001092235A1 (en) 2000-06-01 2001-12-06 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
FR2832152A1 (en) * 2001-11-09 2003-05-16 Aventis Pharma Sa New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
FR2840899B1 (en) * 2002-06-12 2005-02-25 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
DE10143840A1 (en) * 2001-09-06 2003-03-27 Probiodrug Ag New acylated hydroxamates useful for the treatment of e.g. wound healing
HUP0402037A2 (en) 2001-11-09 2005-01-28 Aventis Pharma S.A. Use of 2-Aminothiazoline derivatives as inducible NO-synthetase inhibitors, process for their production and pharmaceutical preparations containing them
CN1622941A (en) 2002-02-28 2005-06-01 普罗西迪恩有限公司 Glutaminyl based DPIV inhibitors
US20040229955A1 (en) * 2003-01-08 2004-11-18 Andersen Niels H. Antibacterial agents
ZA200508439B (en) 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
NZ568459A (en) 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
WO2005027969A1 (en) * 2003-09-24 2005-03-31 Santen Pharmaceutical Co., Ltd. Remedy for eye diseases accompanied by optic nerve injuries
NZ546322A (en) 2003-10-15 2008-11-28 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
WO2008154642A2 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
BG110141A (en) 2008-05-23 2009-12-31 "Софарма" Ад Galanthamine derivatives, methods for their obtaining and use
EP2847168A1 (en) 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
WO2017004560A1 (en) * 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
US20240010642A1 (en) * 2021-01-05 2024-01-11 Southern Research Institute Modulators of programmed death-ligand-1
WO2024076635A2 (en) * 2022-10-05 2024-04-11 Buck Institute For Research On Aging Suppressors of site iq electron leak and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910713A1 (en) * 1990-03-05 1991-09-11 Cephalon Inc Chymotrypsin-like proteases
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
CZ184194A3 (en) * 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
HU221629B1 (en) * 1993-10-01 2002-12-28 Merrell Pharmaceuticals Inc. Peptides inhibiting beta-amyloid protein formation, a process for their preparation and pharmaceutical compositions containing them
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
EP0831920A4 (en) * 1995-06-06 2003-03-19 Athena Neurosciences Inc Novel cathepsin and methods and compositions for inhibition thereof

Also Published As

Publication number Publication date
NO992368D0 (en) 1999-05-14
HRP970627A2 (en) 1998-08-31
PE16999A1 (en) 1999-02-19
CA2267634A1 (en) 1998-05-28
ID22044A (en) 1999-08-26
EA199900490A1 (en) 2000-02-28
IL129083A0 (en) 2000-02-17
KR20000069064A (en) 2000-11-25
NZ334690A (en) 2001-09-28
HUP0100270A2 (en) 2001-08-28
CN1238779A (en) 1999-12-15
WO1998022494A2 (en) 1998-05-28
JP2001503782A (en) 2001-03-21
HUP0100270A3 (en) 2001-09-28
NO992368L (en) 1999-06-21
TR199902938T2 (en) 2002-06-21
EP0942924A2 (en) 1999-09-22
AU5356198A (en) 1998-06-10
AR016751A1 (en) 2001-08-01
YU46097A (en) 2000-10-30
WO1998022494A3 (en) 1998-11-26
CZ122899A3 (en) 1999-10-13
BR9713400A (en) 2000-01-25
TR199902937T2 (en) 2001-01-22
CO4910156A1 (en) 2000-04-24

Similar Documents

Publication Publication Date Title
TR199901133T2 (en) Compounds and methods that inhibit the release and/or synthesis of β-amyloid peptide.
TR199901343T2 (en) To inhibit the release and/or synthesis of β-amyloid peptide using cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions containing them, and such compounds. in methods.
TR199902071T2 (en) Heterocyclic compounds and their use in inhibition of β-amylioid peptide
TR199901132T2 (en) To inhibit the release and/or synthesis of β-amyloid peptide using N-(aryl/heteoaryl) amino acid derivatives, pharmaceutical compositions containing them, and such compounds for methods.
FI962557A7 (en) Use of PLA2 inhibitors in the treatment of Alzheimer's disease
TR200103469T2 (en) Prevention and treatment of amyloidogenic disease
TR199901128T2 (en) N-(aryl/heteroaryacetyl) amino acid esters, pharmaceutical compositions containing it, and the ability to inhibit β-amyloid peptide release and/or its synthesis using such compounds ntems.
LV12438A (en) Metode of preventing and delyaing the onset of alzheimer's disease and composition thereof
PT1083889E (en) TETRA-HYDROFOLANTALINE COMPOUNDS AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
NO20004803L (en) Smilagening and anzurogenin for the treatment of Alzheimer's disease
DE69521700D1 (en) AGENTS AND METHODS FOR TREATING PLAQUE DISEASES
ATE148469T1 (en) CYCLOSPORINS
DK0695758T3 (en) Pentapeptidamides and esters for human cancer inhibition
CY1109368T1 (en) Prevention and treatment of amyloidogenic disease
BR9506820A (en) 4-amino derivatives of mycophenolic acid
NO960120D0 (en) ECF double contrast
DE69519577D1 (en) PREDNISOLONMETASULFOBENZOATE COMPOSITION FOR TREATING INFLAMMATORY DISEASE OF THE COLON
NO20001869L (en) Procedure for the treatment of Alzheimer's disease
TR200000455T2 (en) The use of fanquinone in the treatment of Alzheimer's disease.
DE69838785D1 (en) PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS
DE69420229D1 (en) Pharmaceutical composition for the treatment of AIDS
DE69832722D1 (en) L-THREONATE IRON, PHARMACEUTICAL COMPOSITION AND USE FOR THE IMPROVEMENT AND TREATMENT OF ANEMIA IN HUMANS
ATE210126T1 (en) 4-AMINO-6-SUBSTITUTED MYCOPHENOLIC ACID DERIVATIVES WITH IMMUNOSUPRESSIVE EFFECTS
TR199501328A2 (en) Alzheimer's peptide.
BR9506838A (en) Derivatives of mycophenolic acid substituted in position 5